Clinical Research Directory
Browse clinical research sites, groups, and studies.
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
Sponsor: Vanderbilt University Medical Center
Summary
The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are: 1. Does semaglutide lower the average number of alcoholic beverages participants drink per week? 2. Does semaglutide lower the average number of cigarettes participants smoke per day? 3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and/or smoke tobacco? Researchers will compare the effects of semaglutide to a placebo (a look-alike substance that contains no drug) to see if semaglutide works to lower the alcohol intake among participants each week. Participants will: 1. Take semaglutide for 3 months 2. Visit the research clinic 3 times for checkups and tests 3. Provide blood samples, stool samples, and saliva samples for tests.
Official title: GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV - GL1DER HIV RCT
Key Details
Gender
All
Age Range
18 Years - 89 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-03-31
Completion Date
2030-07-31
Last Updated
2026-03-16
Healthy Volunteers
No
Interventions
Semaglutide (Rybelsus®)
experimental study medication
Placebo
Placebo study product